2cureX AB Market Cap ($1.13 Million)
Market Cap & Net Worth: 2cureX AB (2CUREX)
2cureX AB market cap. 2cureX AB (ST:2CUREX) has a market capitalization of $1.13 Million (Skr10.54 Million) as of November 3, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #30597 globally and #703 in its home market, demonstrating a -30.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 2cureX AB's stock price Skr0.42 by its total outstanding shares 25102916 (25.10 Million). Also see 2cureX AB cash flow conversion for how efficiently the company converts equity into cash flow.
2cureX AB Market Cap History (2017–2026)
2cureX AB market cap history from 2017 to 2026. Data shows change from $15.70 Million to $1.13 Million (-28.12% CAGR). Check 2cureX AB (2CUREX) share price today for real-time trading data and today's change.
Index Memberships
2cureX AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.32 Billion | 0.01% | #234 of 281 |
Weight: 2cureX AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
2cureX AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 2cureX AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 2CUREX net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
35.03x
2cureX AB's market cap is 35.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $15.70 Million | $47.00K | -$3.14 Million | 334.02x | N/A |
| 2018 | $36.30 Million | $7.67 Million | -$7.26 Million | 4.73x | N/A |
| 2019 | $36.88 Million | $11.98 Million | -$7.93 Million | 3.08x | N/A |
| 2020 | $44.71 Million | $15.39 Million | -$7.32 Million | 2.90x | N/A |
| 2021 | $45.38 Million | $7.39 Million | -$18.94 Million | 6.14x | N/A |
| 2022 | $22.02 Million | $90.00K | -$29.77 Million | 244.63x | N/A |
| 2023 | $5.43 Million | $155.00K | -$32.52 Million | 35.03x | N/A |
Competitor Companies of 2CUREX by Market Capitalization
Companies near 2cureX AB in the global market cap rankings as of November 3, 2026. Also see 2cureX AB asset portfolio for a full breakdown of the balance sheet.
Key companies related to 2cureX AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of 2cureX AB (2017–2026)
Market capitalization of 2cureX AB from 2017 to today. Between 2017 and today, 2cureX AB's market cap moved from $15.70 Million to $ 1.13 Million, with a yearly change of -28.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr1.13 Million | -18.29% |
| 2025 | Skr1.39 Million | +21.80% |
| 2024 | Skr1.14 Million | -79.00% |
| 2023 | Skr5.43 Million | -75.34% |
| 2022 | Skr22.02 Million | -51.49% |
| 2021 | Skr45.38 Million | +1.51% |
| 2020 | Skr44.71 Million | +21.25% |
| 2019 | Skr36.88 Million | +1.59% |
| 2018 | Skr36.30 Million | +131.22% |
| 2017 | Skr15.70 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of 2cureX AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.13 Million USD |
| MoneyControl | $1.13 Million USD |
| MarketWatch | $1.13 Million USD |
| marketcap.company | $1.13 Million USD |
| Reuters | $1.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 2cureX AB
2cureX AB (publ) operates as a medical technology company in Europe. ts proprietary IndiTreat test family creates various three-dimensional tumoroids derived from fresh samples of colorectal cancer (CRC) tissue that has been obtained from an individual patient's metastatic colorectal cancer. 2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden.